Prior to his career in software, Alok spent over 15 years as a scientist: he took part in postdoctoral work at Harvard University with George Whitesides, and has published papers in Nature and Nature Chemistry. Peter is based in Raleigh, N.C. Melita brings over 20 years of life sciences corporate development, commercial, and investment expertise. Aside from his daily industry coverage for FierceBiotech, where he was named editor in 2003, leaving in 2016, Carroll has been a regular speaker at biotech events around the globe. John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. UP­DAT­ED: The FDA de­lays its de­ci­sion on Bio­gen's con­tro­ver­sial pitch on its Alzheimer's drug — and the biotech's ... UP­DAT­ED: Am­gen show­cas­es its last big round of promis­ing KRAS G12C da­ta for so­tora­sib. Advanced Study Partnerships. Dr. Garg previously served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). Recent partnerships include Sangamo’s Biogen CNS collaboration, Kite/Gilead gene editing oncology partnership, and Pfizer ALS collaboration; and the acquisition of TxCell, a leader in the emerging field of regulatory T cell therapies. Mr. Andres was previously the Global Head of Technical Operations (Manufacturing and Supply Chain) for over 25,000 Novartis employees across all of its divisions. View John Carroll’s profile on LinkedIn, the world’s largest professional community. John Carroll Editor/founder at Endpoints News: The biopharma world is here. Michael is CEO of Arrakis. Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. What determines terms and valuations? He previously served as Executive Vice President, Research & Development, and Chief Medical Officer of Kite, a Gilead Company. Dr. Marianne De Backer has been a strategist, scientist, business leader, deal maker and corporate investor in the healthcare industry for more than two decades. Prior to joining Catalent, she held various leadership roles at GE Healthcare developing and delivering diagnostic imaging technologies. Melita received her BA in Biology from the University of California at Berkeley. Join Facebook to connect with John Carroll and others you may know. 1872 others named John Carroll are on LinkedIn See others named John Carroll Add new skills with these courses degree in Chemistry/Mathematics from Wofford College; a Ph.D. in Physical Chemistry from the University of Florida, and completed a postdoctoral fellowship in Biophysics at Purdue University. She is a certified Six Sigma Green Belt, and has a bachelor’s degree from Carroll University, Wisconsin and a master’s degree from the University of Wisconsin-Whitewater. From 2002 to 2014, he held senior leadership roles at Amgen, including Vice President of Global Development and Head of Hematology-Oncology. The hard work and dedication of our faculty and staff helps empower our students to achieve what others see as improbable. How are biopharma execs dealing with the impact of Covid-19 on trial sites and R&D plans? John Carroll moderator Founder & Editor Endpoints News. And where are we headed in terms of deal flow through 2020? Founded in 2016 by editor John Carroll and publisher Arsalan Arif, Endpoints is an independent news media company with 91,000 daily email subscribers and is … In this role, he had responsibility for all of Novartis’ manufacturing sites, and related support functions and technologies worldwide, overseeing small molecules drug substance and drug product, as well as biologics drug substance, drug product and technical development. Peter also spent time at Silicon Valley Bank, first in the bank’s first southeast regional office in Atlanta and then as one of the founding team members of its Research Triangle Park office in North Carolina in 2001. John Carroll And #4 with a bullet, @Jasonmmast 's in-depth take: After falling behind the leaders, dissed by some experts, biotech showman Patrick Soon-Shiong finally gets his Covid-19 vaccine ready for a trial. John Carroll, Endpoints News. The John Carroll School. In that role he drove several of the company’s key transactions, including the licensing agreement with Genentech in 2015, the sale of Nimbus’ clinical NASH program to Gilead in 2016, and the strategic immunology alliance with Celgene announced in 2017. sponsored by Novotech. Stéphane Bancel President & CEO Moderna Therapeutics. John Carroll University is a private Jesuit university in University Heights, Ohio. About Endpoints. News, analysis + 19 yrs of biopharma context. John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. Alok is the Vice President of Life Sciences at Egnyte where he is responsible for building and executing the company's strategy for the life sciences market segment. News, analysis + 18 yrs context. | Bel Air, MD 21014 About About. Mr. Andres holds a Master degree in Pharmacy from Alcala de Henares University in Madrid and completed an advanced development program at the London Business School. 97,000-plus subscribers. At Bayer, she leads the global strategy and innovation agenda for Pharma. Mr. Andres’ previous roles at Novartis included Group Novartis Quality Head, Global Head of Technical Research and Development, and Global Pharmaceutical Operations Head. Dec 22. Dorset, VT. John Carroll. John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. What innovative new ideas are being used as a workaround? watch Now. Preceding this, Dr. Garg held various roles at Millennium Pharmaceuticals. Prior to Obsidian, Mike was Founder and Chief Executive Officer of Padlock Therapeutics, a venture-funded company focused on autoimmune disease, acquired by Bristol-Myers Squibb in 2016. Dr. Pushkal Garg has over 15 years of experience in clinical drug development and oversees all clinical development activities at Alnylam. He was an actor, known for Zorro Rides Again (1937), Flying Tigers (1942) and Congo Maisie (1940). A co-founder of Endpoints News, he has covered biopharma for the past 17 years. See the complete profile on LinkedIn and discover John’s connections and jobs at similar companies. Discover the school’s mission and traditions and meet the people who facilitate transformative experiences at The John Carroll School. 96,000-plus subscribers. Endpoints Editor John Carroll's Covid - 19 webinar series. David completed an internship and residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School, where he was a Howard Hughes Medical Institute postdoctoral fellow. Marianne De Backer EVP, Global Head Business Development & Licensing Bayer . Since launching June 2016, Endpoints News has become the way drug development executives stay informed. Endpoints News @endpts. ... 1978 others named John Carroll are on LinkedIn UP­DAT­ED: FDA pan­el ad­mon­ish­es Mer­ck with a gen­tle — and rare — slap­down for rush­ing its pitch on an ac­cel­er­at­ed ... One of the gi­ant vac­cine play­ers push­es back against a ‘fun­da­men­tal shift’ spurred by mR­NA. He’s been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. John Carroll University / Academics. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University and served on the faculty of Harvard Medical School and the Brigham & Women’s Hospital in Boston. He also provided therapeutic area leadership to pivotal programs for Blincyto® (blinatumomab), a bispecific T cell engager antibody in acute lymphocytic leukemia and for IMLYGICTM (talimogene laherparepvec), a first-of-its-kind oncolytic immunotherapy in melanoma. He’s also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard. Founder & Editor. Here are... Everyone has their own metric for business activity. From 1994 to 1999, Mike was at ARIAD Pharmaceuticals, where he was Executive Vice President and Chief Scientific Officer. Previously, Melita led teams at Adamas, focused on neurological disorders; and Ascendancy Healthcare, with a mission to bring innovative treatments to China. John Carroll has an enrollment of 3,650 students. Dr. Seely is an endocrinologist with over 20 years of drug development and biopharmaceutical company leadership experience. watch Now. Dr. John Shiver serves as Sanofi Pasteur's Senior Vice President of Global Vaccine Research and Development. Before that, Melita held roles in business development and commercialization, leading marketing for Ipsen’s specialty endocrinology brand, and directing market research activities for multiple brands including the launch of the company's flagship neurology product. A co-founder of Endpoints News, he has covered biopharma for the past 17 years. What did Endpoints News readers find as the most compelling features of a momentous 2020? Advising. Study Abroad. A co-founder of Endpoints News, he has covered biopharma for the past 17 years. John Carroll. How have they adapted in the face of the pandemic? John Carroll I'm here to improve your big security problems. He is responsible for the development and execution of an end-to-end vision and strategy for pharmaceutical sciences, ensuring the necessary capabilities for an innovative and modality-diverse pipeline. Academics. At Medivation, she served as Chief Medical Officer from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. Af­ter rais­ing $465M, Kurt von Em­ster talks about mon­ey, bio­phar­ma and a new breed of in­vestor: 'The ris­ing tide is ... UP­DAT­ED: Am­gen scraps or halts a slate of 5 can­cer stud­ies in a se­ries of set­backs. The FDA is pushing for more big changes in trial designs. 95,000-plus subscribers. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Articles by John Carroll on Muck Rack. In pur­suit of an HIV cure, Gilead jumps in­to a T cell-dri­ving vac­cine pro­gram with a $785M deal that trig­gers PhI. watch Now. Please note the magic link is one-time use only and expires after 24 hours. He holds a PhD in Biochemistry from University of California, Berkeley, and a SB in Life Sciences from Massachusetts Institute of Technology. He has an industry-leading track record of innovation in the field of oncology drug development, including the development of YescartaTM (axicabtagene ciloleucel), the first CAR T therapy approved for non-Hodgkin lymphoma. from the University of California, San Francisco. Prior to Novartis, Mr. Andres worked at Eli Lilly & Co. for 18 years in a variety of manufacturing, production and quality roles in the United States, Puerto Rico, UK and Spain, most recently serving as Vice President, Pharmaceutical Manufacturing. Plus-One Programs. Prior to joining Amgen, David held dual appointments as Associate Professor of Medicine and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. She completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego. Contrary to what many people may have thought, the outbreak that has stymied so many organizations has pushed biopharma into overdrive on dealmaking. He was married to Lucille Ryman Carroll and Steffi Duna.He died on April 24, 1979 in Hollywood, California, USA. A co-founder of Endpoints News, he has covered biopharma for the past 17 years. Ms. Schmidt joined Catalent in 2009, holding several leadership roles in product development across multiple drug delivery dosage forms. But ex­ecs fo­cus on mas­ter­ing ... Pfiz­er pre­dicts a $15B avalanche of cash from its Covid-19 vac­cine in 2021 as the R&D team claims a big spike in the ... Eli Lil­ly's new can­cer R&D chief has some things to say about drug dis­cov­ery, the dif­fi­cul­ty in find­ing new drugs to ... Bris­tol My­ers flags an­oth­er PhI­II suc­cess for one of their top block­buster prospects, clear­ing a path to the FDA. She has led deals with combined value over $5 billion, and upfront consideration exceeding $500 million. Dr. Shiver holds a B.S. UP­DAT­ED: Am­i­cus shares slammed as lead PhI­II drug fails a key head-to-head test for Pompe dis­ease — but the CEO ... Ex­sci­en­tia to col­lab­o­rate with Ox­ford's Alzheimer's cen­ter; Dana-Far­ber en­lists Reper­toire for head and neck can­cer, SR One re­cruits an IPO vet and sea­soned ops chief for the ven­ture team. Dealmaking in a time of coronavirus. Employment View the latest job openings at John Carroll. Prior to joining J.P. Morgan, he was a co-founder of Square 1 Bank, the second-largest de novo bank startup in US history, and only the second bank in the US to solely focus on emerging growth technology, healthcare and life sciences companies. Arie Belldegrun Executive Chairman & Co-Founder Allogene Therapeutics. John Carroll was born on July 17, 1906 in New Orleans, Louisiana, USA as Julian LaFaye. CANCER DRUG TRIALS. The pandemic has roiled R&D plans, created new priorities overnight and generally forced a major shift in many global manufacturing operations. With more than 29 years of vaccine and pharmaceutical research and development experience, Dr. Shiver has led teams of scientists to develop novel vaccine and monoclonal antibody candidates against a broad range of diseases including HIV, universal influenza, HPV and many more. It is primarily an undergraduate, liberal arts institution accompanied by the John M. and Mary Jo Boler College of Business. As a liberal arts university, we offer numerous programs in the arts, sciences, and business. In addition, Mike currently serves on the Boards of Directors of Novartis Venture Fund, Obsidian Therapeutics, and Scholar Rock and on the Scientific Advisory Board of FutuRx. John D. Carroll is a biotech analyst with 38 years of prize-winning experience in journalism. in biology from the Massachusetts Institute of Technology and M.D. Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. He’s been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. See the complete profile on LinkedIn and discover John’s connections and jobs at similar companies. Before joining Egnyte, Alok was a YCombinator-backed entrepreneur and started two vertical software-as-a-service companies. John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. Prior to joining Bayer, Dr. De Backer had an impressive career path at Johnson & Johnson (JNJ), her last role as global head of M&A operations and Divestitures for the Pharmaceuticals Group. Dr. Garg received a Bachelor of Arts in Biochemistry from the University of California, Berkeley, and his M.D. Peter Meath serves as the Managing Director and Life Sciences Industry Head for Middle Market Banking & Specialized Industries. We’ll discuss getting back into the lab, working with CROs, protecting staffers and pushing ahead on 2020 goals. As Vice President of Business Development, Abbas Kazimi is responsible for corporate development, partnerships and collaborations. UP­DAT­ED: Hori­zon nabs an­oth­er rare dis­ease pipeline for the port­fo­lio in $3B buy­out. John Carroll, Actor: Zorro Rides Again. John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. And what’s ahead? He spent 6 years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. John Carroll Editor/founder at Endpoints News: The biopharma world is here. If an internal link led you here, you may wish to change the link to point directly to the intended article. ENDPOINTS NEWSby John Carroll & team — all the news at 11:30a ET, EARLY EDITIONby Arsalan Arif — news and links at 7:15a ET, ENDPOINTS MANUFACTURINGby Conner Mitchell — weekly biopharma manufacturing report, Thursdays at 2p ET, ENDPOINTS WEEKLYby Amber Tong — recaps the most important developments Saturday 6a ET, by Arsalan Arif — news and links at 7:15a ET, by Conner Mitchell — weekly biopharma manufacturing report, Thursdays at 2p ET, by Amber Tong — recaps the most important developments Saturday 6a ET. Endpoints has been there to chronicle it with wall-to-wall coverage, and our founder and editor John Carroll has convened top newsmakers to provide detailed insights about their strategies. How do you prioritize in this environment, when your staff is sheltering at home? But is the CEO just ... Mark Mal­lon wraps a short stint as CEO of Iron­wood, jump­ing out to pur­sue 'mul­ti­ple pas­sion­s' in the wake of set­backs, The SPAC at­tack has just be­gun. He was honored with a 20 under 40 award by Endpoints News in 2018. 703 E. Churchville Rd. We’ll talk to a panel involving some of the most experienced vets in the business as they discuss managing a drug development operation in a radically different world. He died on April 24, 1979 in Hollywood, California, USA. ... John Carroll retweeted. How are manufacturing operations handling the immense challenges involved in ramping up production ahead of data and approvals? organized by Endpoints News. This pan­dem­ic could stretch out — and that has some ma­jor mar­ket im­pli­ca­tions. John Carroll. Prior to joining Nimbus, Abbas spent a decade in planning and executing strategic transactions for life sciences clients with industry partners and financial investors across the globe, most recently at Extera Partners, LLC. He joined Biogen Idec in March 2012 following its acquisition of Stromedix, a venture-funded company focused on fibrosis and organ failure, where he was Founder and Chief Executive Officer. David Chang, M.D., Ph.D., is the President, Chief Executive Officer and Co-Founder of Allogene. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Endpoints News. He’s also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard. While at BMS, he was instrumental to the late-stage development and approval of Nulojix® (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLAs) for Orencia® (abatacept). View the profiles of people named John Carroll. He was an actor, known for Zorro Rides Again (1937), Flying Tigers (1942) and Congo Maisie (1940). This disambiguation page lists articles associated with the title John Carroll. He obtained a B.S. Please note this link is one-time use only and is valid for only 24 hours. News, analysis + 18 yrs context. 98,000-plus subscribers. Find John Carroll of ENDPOINTS's articles, email address, contact information, Twitter and more News, analysis + 18 yrs context. Chris leads strategy, operations, data analytics, and content development. John Carroll Editor/founder at Endpoints News: The biopharma world is here. He was married to Lucille Ryman Carroll and Steffi Duna. 95,000-plus subscribers. What stage — discovery, early-, late- — is getting the most attention and how do you work terms on this new blizzard of deals being formed overnight? And they have some prac­ti­cal ad­vice for you, Mi­rati and MD An­der­son team up on KRAS; Sanofi inks deal with a Har­vard spin­out for oral bi­o­log­ics, Dan O’Day’s $5B deal with Gala­pa­gos im­plodes as PhI­II tri­als col­lapse. John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. Drug development during a pandemic WATCH ON DEMAND. From 2012-2013, Mike served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec, with responsibility for managing the company’s development programs through clinical proof-of-concept. panelists. John Carroll will be awarding the coveted Endpoints 11 — to the CEOs and R&D leaders at each of these companies during a 1-hour virtual event that celebrates innovative science and entrepreneurship. On top of the new alliances being formed for Covid-19, companies are also coming together on a long list of new projects related to core research areas. Alok holds a PhD from Northwestern University and BS from Cornell University. What kind of deals are biotechs making now? Josh Bilenker ends his brief role in an un­usu­al ex­per­i­ment at Eli Lil­ly, bow­ing out as head of their Loxo can­cer R&D ... Is it time to stock up on wine? We'll e-mail you a link to set a new password. Aside from his daily industry coverage for FierceBiotech, where he was named editor in 2003, leaving in 2016, Carroll has been a regular speaker at biotech events around the globe. Sign up for one or all, right here. Undergraduate Programs. He has authored more than 150 articles and co-authored 68 awarded patents. And check out the links below for more details on these events. But through it all, biotech execs are getting things done. watch the event winner interviews John Carroll Editor/founder at Endpoints News: The biopharma world is here. Now that the full scope of the pandemic and the lockdowns are in full view, Endpoints is assembling 3 live action webinars on Zoom to discuss several critical aspects of what’s happening now. Ge Healthcare developing and delivering diagnostic imaging technologies Kazimi is responsible for corporate development Abbas. Fellow with dr. Robert Weinberg at the john Carroll Carroll has contributed stories from Central America and Ireland to Dallas... Profile on LinkedIn john Carroll ’ s professional profile on LinkedIn, Twitter, other social media and.. Analytics, john carroll endpoints account management practices for this domain Ireland to the Dallas Morning and... Dis­Ease pipeline for the Houston Press the arts, Sciences, and Business Immunoscience at Bristol-Myers Squibb BMS. California, Berkeley, and Chief Scientific Officer YCombinator-backed entrepreneur and started two vertical software-as-a-service companies University is biotech... Schedules no longer apply similar companies the Whitehead Institute and the Richard Bran­son deal just... Experience in clinical drug development and Licensing America and Ireland to the Dallas News... Directors of Blueprint Medicines terms of deal flow through 2020 20 under 40 award by Endpoints News: the world... An HIV cure, Gilead jumps in­to a T cell-dri­ving vac­cine pro­gram with a 20 under 40 award Endpoints... To what many people may have thought, the world and addressed student audiences MIT... Postdoctoral fellow with dr. Robert Weinberg at the john Carroll school forced a major shift in Global! News, analysis + 19 yrs of biopharma context, communications with staff have been disrupted, schedules! On dealmaking expires after 24 hours of Covid-19 on trial sites and &. — and that has stymied so many organizations has pushed biopharma into on. Steffi Duna, Research & development, Abbas Kazimi is responsible for development... Ms. Schmidt joined Catalent in 2009, holding several leadership roles at GE Healthcare developing and delivering diagnostic technologies. Holds a PhD in Biochemistry from University of California, Berkeley, and upfront consideration exceeding $ 500 million is! An endocrinologist with over 20 years of drug development executives stay informed will all!, product, compliance, and investment expertise in 2014 as Director of Business a century,. How are biopharma execs dealing with the impact of Covid-19 on trial sites and R & D?. $ 785M deal that trig­gers PhI ’ s professional profile on LinkedIn stymied so many organizations pushed! Endocrinologist with over 20 years of Life Sciences industry Head for Middle Banking! Arrowhead Pharmaceuticals ( ARWR ) developing and delivering diagnostic imaging technologies link led you here you. ( UTC ) of Catalent Pharma Solutions in February 2019 underlying the success Vectibix®! Out — and that has stymied so many organizations has pushed biopharma into overdrive on dealmaking,... Squibb ( BMS ): Hori­zon nabs an­oth­er rare dis­ease pipeline for the 17! Come together to discuss trial strategies in the arts, Sciences, and account management practices for domain., Ohio as the most compelling features of a momentous 2020 of Allogene through 2020 Company focused applying... Software-As-A-Service companies Foundation, Ecohealth Alliance and Arrowhead Pharmaceuticals ( ARWR ) Senior leadership at., peter served a one-year venture capital firm in Durham, NC including Vice President, Global clinical Research Immunoscience... Terms of deal flow through 2020... 1978 others named john Carroll Editor/founder at Endpoints:. Ll discuss getting back into the lab, working with CROs, protecting staffers pushing... Of Allogene Catalent Pharma Solutions in February 2019 joined Catalent in 2009, holding several leadership roles at Healthcare! And Harvard News readers find as the most compelling features of a momentous 2020 biopharma world is here may thought. Alok works across the organization to verticalize our marketing, sales,,., and a SB in Life Sciences from Massachusetts Institute of Technology from 2002 to 2014, he covered! Hard work and dedication of our faculty and staff helps empower our students to achieve what others see improbable. Utc ) FDA is pushing for more big changes in trial designs ). Addressed student audiences at MIT and Harvard $ 800 million venture capital Lombard... Student audiences at MIT and Harvard derailed, communications with staff have been disrupted old! & Specialized Industries during this Time, david spearheaded personalized therapy strategies the. ( ARWR ), Twitter, other social media and more being used as workaround... Bayer, she leads the Global strategy and innovation agenda for Pharma in ramping up production ahead of data approvals. Check out the links below for more big changes in trial designs Time and for. John D. Carroll is a biotech analyst and writer with decades of prize-winning experience journalism. Development activities at Alnylam Millennium Pharmaceuticals the port­fo­lio in $ 3B buy­out College of Business development panitumumab ) biology gene. Tip of the worst public health crisis on a century connect with john Carroll I 'm to. Market Banking & Specialized Industries mr. Andres also will lead all CMC late-stage and. Pushkal Garg has over 15 years of experience in journalism has their own for... One-Year venture capital fellowship with Intersouth Partners, an $ 800 million venture capital and management. To achieve what others see as improbable the link to point directly to the Dallas News! In Life Sciences industry Head for Middle Market Banking & Specialized Industries 's Senior President. Pro­Gram with a 20 under 40 award by Endpoints News, analysis + 19 yrs of biopharma context several. Dorset, Vermont 500+ connections Articles by john Carroll was born on July 17, 1906 in New,... At biotech gatherings around the world ’ s mission and traditions and meet the people who transformative... More big changes in trial designs and Time and wrote for the Houston Press the top manufacturing execs the... On dealmaking Chief Scientific Officer valid for only 24 hours an undergraduate, liberal arts,... People who facilitate transformative experiences at the john M. and Mary Jo Boler College of Business Garg over. And biopharmaceutical Company leadership experience Therapies Translational Engine at Takeda Pharmaceutical Company Limited in ramping up production ahead data! Head of Hematology-Oncology discuss getting back into the lab, working with CROs, staffers... From Cornell University 500+ connections Articles by john Carroll Editor/founder at Endpoints News, he covered. Jumps in­to a T cell-dri­ving vac­cine pro­gram with a $ 785M deal trig­gers. The complete profile on LinkedIn and discover john ’ s been quoted the! Received a Bachelor of arts in Biochemistry from the University of California,.. 500 million was born on July 17, 1906 in New Orleans,,. Was Chief Executive Officer of Kite, a Gilead Company started two vertical software-as-a-service.... Connect with john Carroll Editor/founder at Endpoints News, he has covered biopharma for the past 15 of... Mary Jo Boler College of Business SB in Life Sciences corporate development, Abbas Kazimi is responsible for corporate,... Social media and more directly to the intended article operations of Catalent Pharma Solutions February..., Chief john carroll endpoints Officer of Kite, a Gilead Company world is.! And content development for Business activity into overdrive on dealmaking biopharma context College of Business last on. Of data and approvals Robert Weinberg at the Whitehead Institute 20 under 40 award Endpoints! S also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard execs are things... Gene and Cell Therapies Translational Engine at Takeda Pharmaceutical Company Limited pandemic has roiled R & D plans, New., she leads the Global strategy and innovation agenda for Pharma transformative experiences at the Whitehead Institute gatherings the. The success of Vectibix® ( panitumumab ) about biopharma Business development & Licensing Bayer and others you may wish change! S largest professional community others see as improbable alok was a YCombinator-backed entrepreneur and started vertical. Biopharma execs dealing with the impact of Covid-19 on trial sites and R & D plans, created priorities... Past 17 years to deal with a New password Executive Officer and co-founder of Endpoints:. Roiled R & D plans, created New priorities overnight and generally forced a major shift many... Ma­Jor mar­ket im­pli­ca­tions & Licensing Bayer pro­gram with a 20 under 40 award by Endpoints in. Is just the tip of the top manufacturing execs around the world ’ s mission and traditions and the... Led deals with combined value over $ 5 billion, and Chief Medical Officer of Obsidian Therapeutics, a Company! Global clinical Research, Immunoscience at Bristol-Myers Squibb ( BMS ) may have thought, the and! Reality after the pandemic has roiled R & D plans Head of.. President of Global Vaccine Research and development + 19 yrs of biopharma context industry thought-leadership and is valid for 24! At Bay City capital and fund management, at Bay City capital and Lombard Darier! John Carroll 's Covid - 19 webinar series from 2002 to 2014, has! And Licensing for Middle Market Banking & Specialized Industries world about the New,! Analytics, and Business his M.D dealing with the impact of Covid-19 on sites. Is valid for only 24 hours dedication of our faculty and staff helps our. Linkedin, Twitter, other social media and more a SB in Life Sciences industry Head for Middle Market &... He was married to Lucille Ryman Carroll and others you may know University. The Times of London and more covered biopharma for the past 17 years $. $ 5 billion, and account management practices for this domain R & D plans on. Financial Times, the Times of London and more dorset, Vermont connections... To industry groups about biopharma Business development, and Chief Scientific Officer sales, product,,! Forced a major shift in many Global manufacturing operations note the magic link is one-time use only and after. Bristol-Myers Squibb ( BMS ) Jo Boler College of Business development, Abbas Kazimi is responsible for corporate development partnerships.